Testing effectiveness (Phase 2)Study completedNCT04551898
What this trial is testing
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
Who this might be right for
Covid19
BeiGene 181